M.R.L. Stratford

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

G. M. Tozer, Vivien E. Prise, John Wilson et al. · PubMed · 1999 · 324 citations

Medicine, Oncology, Pharmacology +17

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.

Susan Galbraith, David J. Chaplin, Frank Lee et al. · PubMed · 2001 · 165 citations

Medicine, Oncology, Pharmacology +16

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

Gordon Rustin, Gavin Shreeves, Paul Nathan et al. · British Journal of Cancer · 2010 · 130 citations · Full text

Medicine, Oncology, Pharmacology +17

Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy

Mladen Korbelik, C.S. Parkins, Hiroshi Shibuyà et al. · British Journal of Cancer · 2000 · 113 citations · Full text

Medicine, Oncology, Pharmacology +13

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

Gordon Rustin, Christopher Bradley, Susan Galbraith et al. · British Journal of Cancer · 2003 · 105 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13